Effects of Ezetimibe on Cholesterol Metabolism in HIV-infected Patients with Protease Inhibitor-associated Dyslipidemia: a Single-arm Intervention Trial

Overview

Journal BMC Infect Dis

Publisher Biomed Central

Specialty Infectious Diseases

Date 2014 Sep 12

PMID 25209653

Citations 1

Authors

Pere Leyes

Esteban Martinez

Maria Larrousse

Montserrat Cofan

Joan Trabal

Ana Maria Perez-Heras

Maria T Forga

Emilio Ros

Affiliations

Soon will be listed here.

Abstract

Background: The effects of ezetimibe on cholesterol metabolism in HIV-infected patients receiving boosted protease inhibitors have not been thoroughly assessed. The aim of this study was to assess cholesterol homeostasis in patients with PI associated dyslipidemia and its relationship with the response to treatment with the cholesterol-absorption inhibitor ezetimibe.

Methods: Fifteen patients with ritonavir-boosted PI-containig therapy and LDL-cholesterol > 3.36 mmol/L (>130 mg/dL) were assessed at baseline and after an 8-week course of ezetimibe 10 mg/d. Serum non-cholesterol sterols were measured at each visit as markers of cholesterol synthesis and absorption. Total-, LDL-, and HDL-cholesterol triglycerides, apolipoproteins A1 and B, high sensitivity C-reactive protein, CD4 cells and HIV-1 RNA were also measured.

Results: Ezetimibe treatment was well tolerated in all patients and resulted in significant reductions in total cholesterol (-11.4%, p = .002), LDL-cholesterol (-20.4%, p = .003), non-HDL-cholesterol (-13.4%, p = .002) and apolipoprotein B (-9.1%, p = .021). Treatment with ezetimibe was associated with decreased cholesterol absorption markers (campesterol-to-cholesterol ratio -43.0%, p = .001; sitosterol-to-cholesterol ratio -41.9%, p = .001) and increased synthesis markers (lathosterol-to-cholesterol ratio 53.2%, p = .005). Baseline absorption or synthesis markers were unrelated to the response to treatment. CD4 cell count and plasma HIV-1 RNA remained unchanged.

Conclusions: The level of cholesterol absorption or synthesis does not appear to be a major determinant of the responsiveness to ezetimibe in patients on ritonavir-boosted PI-containing therapy.

Trial Registration: EudraCT: 2006-006156-36.

Citing Articles

Hypolipidemic, antioxidant and anti-atherosclerogenic effect of aqueous extract leaves of Cassia. occidentalis Linn (Caesalpiniaceae) in diet-induced hypercholesterolemic rats.

Fidele N, Joseph B, Emmanuel T, Theophile D BMC Complement Altern Med. 2017; 17(1):76.

PMID: 28122565 PMC: 5264340. DOI: 10.1186/s12906-017-1566-x.

References

Friis-Moller N, Reiss P, Sabin C, Weber R, Monforte A, El-Sadr W . Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007; 356(17):1723-35. DOI: 10.1056/NEJMoa062744. View

Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, Monforte A . Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. AIDS. 2003; 17(8):1179-93. DOI: 10.1097/01.aids.0000060358.78202.c1. View

Matthan N, Lichtenstein A, Ausman L, Jones P . Deuterium uptake and plasma cholesterol precursor levels correspond as methods for measurement of endogenous cholesterol synthesis in hypercholesterolemic women. Lipids. 2000; 35(9):1037-44. DOI: 10.1007/s11745-000-0616-9. View

Sudhop T, Lutjohann D, von Bergmann K . Sterol transporters: targets of natural sterols and new lipid lowering drugs. Pharmacol Ther. 2005; 105(3):333-41. DOI: 10.1016/j.pharmthera.2004.10.011. View

Escurriol V, Cofan M, Moreno-Iribas C, Larranaga N, Martinez C, Navarro C . Phytosterol plasma concentrations and coronary heart disease in the prospective Spanish EPIC cohort. J Lipid Res. 2009; 51(3):618-24. PMC: 2817591. DOI: 10.1194/jlr.P000471. View

Silverberg M, Leyden W, Hurley L, Go A, Quesenberry Jr C, Klein D . Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection. Ann Intern Med. 2009; 150(5):301-13. DOI: 10.7326/0003-4819-150-5-200903030-00006. View

Lakoski S, Xu F, Vega G, Grundy S, Chandalia M, Lam C . Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin. J Clin Endocrinol Metab. 2009; 95(2):800-9. PMC: 3079219. DOI: 10.1210/jc.2009-1952. View

Hiramitsu S, Ishiguro Y, Matsuyama H, Yamada K, Kato K, Noba M . The effects of ezetimibe on surrogate markers of cholesterol absorption and synthesis in Japanese patients with dyslipidemia. J Atheroscler Thromb. 2010; 17(1):106-14. DOI: 10.5551/jat.1578. View

Carr A, Samaras K, Thorisdottir A, Kaufmann G, Chisholm D, Cooper D . Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999; 353(9170):2093-9. DOI: 10.1016/S0140-6736(98)08468-2. View

10.

Kinlay S . Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis. J Am Coll Cardiol. 2007; 49(20):2003-9. DOI: 10.1016/j.jacc.2007.01.083. View

11.

Baker J, Henry W, Neaton J . The consequences of HIV infection and antiretroviral therapy use for cardiovascular disease risk: shifting paradigms. Curr Opin HIV AIDS. 2009; 4(3):176-82. PMC: 2879578. DOI: 10.1097/COH.0b013e328329c62f. View

12.

Dujovne C, Ettinger M, McNeer J, Lipka L, LeBeaut A, Suresh R . Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol. 2002; 90(10):1092-7. DOI: 10.1016/s0002-9149(02)02798-4. View

13.

Miettinen T, Tilvis R, Kesaniemi Y . Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. Am J Epidemiol. 1990; 131(1):20-31. DOI: 10.1093/oxfordjournals.aje.a115479. View

14.

Assmann G, Kannenberg F, Ramey D, Musliner T, Gutkin S, Veltri E . Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe-statin therapies on non-cholesterol sterols in patients with primary hypercholesterolemia. Curr Med Res Opin. 2007; 24(1):249-59. DOI: 10.1185/030079908x253663. View

15.

Wohl D, Waters D, Simpson Jr R, Richard S, Schnell A, Napravnik S . Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy. Clin Infect Dis. 2008; 47(8):1105-8. PMC: 5909814. DOI: 10.1086/592116. View

16.

von Bergmann K, Sudhop T, Lutjohann D . Cholesterol and plant sterol absorption: recent insights. Am J Cardiol. 2005; 96(1A):10D-14D. DOI: 10.1016/j.amjcard.2005.03.014. View

17.

Hui D . Effects of HIV protease inhibitor therapy on lipid metabolism. Prog Lipid Res. 2003; 42(2):81-92. DOI: 10.1016/s0163-7827(02)00046-2. View

18.

Sudhop T, Lutjohann D, Kodal A, Igel M, Tribble D, Shah S . Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation. 2002; 106(15):1943-8. DOI: 10.1161/01.cir.0000034044.95911.dc. View

19.

Friis-Moller N, Sabin C, Weber R, Monforte A, El-Sadr W, Reiss P . Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003; 349(21):1993-2003. DOI: 10.1056/NEJMoa030218. View

20.

Coll B, Aragones G, Parra S, Alonso-Villaverde C, Masana L . Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients. AIDS. 2006; 20(12):1675-7. DOI: 10.1097/01.aids.0000238418.43937.3b. View